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Protein modification by small ubiquitin-related modi-
fier proteins (SUMOs) controls diverse cellular
functions. Dysregulation of SUMOylation or deSU-
MOylation processes has been implicated in the
development of cancer and neurodegenerative
diseases. However, no small-molecule inhibiting
protein SUMOylation has been reported so far.
Here, we report inhibition of SUMOylation by gink-
golic acid and its analog, anacardic acid. Ginkgolic
acid and anacardic acid inhibit protein SUMOylation
both in vitro and in vivo without affecting in vivo ubiq-
uitination. Binding assays with a fluorescently
labeled probe showed that ginkgolic acid directly
binds E1 and inhibits the formation of the E1-SUMO
intermediate. These studies will provide not only
a useful tool for investigating the roles of SUMO
conjugations in a variety of pathways in cells, but
also a basis for the development of drugs targeted
against diseases involving aberrant SUMOylation.
INTRODUCTION
Posttranslational modifications of proteins are the important
mechanisms that regulate protein function, activity, or localiza-
tion. These include phosphorylation, acetylation, methylation,
and ubiquitination, which have been implicated in a variety of bio-
logical processes such as intercellular signaling, gene expres-
sion, and cell cycle control (Huang and Berger, 2008; Pickart,
2001; Yang andSeto, 2008). Perturbationswithin thesemodifica-
tion systems have been shown to contribute to the etiology of
various human diseases. Therefore, small-molecule compounds
that modulate posttranslational modifications of proteins are
thought to have potential to regulate biological processes and
diseases. In recent years, posttranslational conjugation of small
ubiquitin-related modifier protein (SUMO) to a specific lysine
residue in a protein target has been shown as one of the majorChemistry & Biology 16, 133protein modifications that regulate various biological systems.
Although SUMO and ubiquitin share structural similarities, their
functional roles in cells are quite different. Conjugation of
SUMOhas been shown to alter diverse protein functions through
changes in activity, subcellular localization, or stability, and it is
thus involved in the regulation of many cellular pathways
including transcription, intracellular transport, DNA repair, repli-
cation, and cell signaling (Johnson, 2004). SUMO modification
has also been involved in tumorigenesis (Alarcon-Vargas and
Ronai, 2002) and neurodegeneration (Dorval and Fraser, 2007),
suggesting that SUMO modification is an important target for
the development of drugs against these diseases.
SUMOylation is mediated by an enzymatic cascade reaction
similar to ubiquitination (Johnson, 2004). In the first step, the
SUMO precursor is processed by SUMO proteases to expose
the C-terminal diglycine, which can then form a thioester bond
with a cystein residue in the SUMO-activating enzyme (E1), the
Aos1/Uba2 heterodimer, in an ATP-dependent manner. In the
second step of the reaction, SUMO is transferred from E1 to
a cystein residue in the SUMO-conjugating enzyme (E2), Ubc9,
through another thioester bond. In the last step, SUMO forms
an isopeptide bond with the 3-amino group of the target lysine
residue through the function of E2 and the SUMO ligase (E3).
Whereas E1 and E2 are sufficient for the in vitro SUMOylation
of various substrates, several E3s facilitate both in vivo and
in vitro conjugation (Johnson, 2004). Three types of E3 enzymes,
PIAS, RanBP2, and PC2, have been described, all of which
interact with Ubc9 and enhance both in vivo and in vitro SUMOy-
lation (Johnson, 2004). SUMO can be deconjugated by isopepti-
dases, which cause removal of SUMO from its substrate
(Johnson, 2004). These enzyme reactions are the potential
targets for small molecules that control SUMOylation. Therefore,
an in situ SUMOylation assay and a chemoluminescence-based
assay for detecting SUMOylation have been developed and can
be used for high-throughput screening for inhibitors of SUMOy-
lation (Saitoh et al., 2006; Rouleau et al., 2008). Several chemical
inhibitors of the ubiqutin E1 enzyme have been recently
described (Sekizawa et al., 2002; Tsukamoto et al., 2005; Yang
et al., 2007). In the case of SUMOylation, however, no chemical
inhibitors have been reported so far.–140, February 27, 2009 ª2009 Elsevier Ltd All rights reserved 133
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Ginkgolic Acid as an Inhibitor of SUMOylationIn this study, we screened for inhibitors of protein SUMOyla-
tion from a botanical extract library by using an in situ SUMOyla-
tion screening system. We found inhibitory activity of protein
SUMOylation in the extract ofGinkgo biloba leaves and identified
ginkgolic acid as an inhibitor. Ginkgolic acid and its structural
analog anacardic acid inhibited both in vitro and in vivo SUMOy-
lation, but not in vivo ubiquitination. Ginkgolic acid directly
bound E1 and impaired the formation of the E1-SUMO interme-
diate. Discovery of the low-molecular inhibitor of protein SUMO-
lylation will provide useful information about the enzymatic
mechanism and drug development.
RESULTS AND DISCUSSION
Using an in situ cell-based SUMOylation assay method (Saitoh
et al., 2006), we screened 500 samples of botanical extracts
including food ingredients and found inhibitory activities of
protein SUMOylation in 2 samples, including extract of Gingko
biloba leaves. An in vitro SUMOylation assay with RanGAP1-
C2, a C-terminal fragment of RanGAP1, as a substrate revealed
that the extract ofGingko biloba leaves inhibited protein SUMOy-
lation at the concentration of 100 mg/ml (Figure 1A). As ginkgolic
acid and ginkgolides are two major components of the extract of
Gingko biloba leaves, we first tested the effect of these
compounds on the in vitro inhibition of protein SUMOylation;
ginkgolic acid (Figure 1C), but not ginkgolides, completely
inhibited the SUMOylation of RanGAP1-C2 in vitro at 10 mM
(Figure 1B). Ginkgolic acid is an alkylphenol derivative that
causes allergic skin inflammation. In addition to ginkgolic acid,
anacardic acid (Figure 1C), a structurally related analog of
ginkgolic acid known to be a histone acetyltransferase (HAT)
inhibitor (Balasubramanyam et al., 2003), also inhibited the
in vitro SUMOylation of RanGAP1-C2 (Figure 1D). IC50 values of
ginkgolic acid and anacardic acid against the SUMOylation of
RanGAP1-C2 are 3.0 mM and 2.2 mM, respectively (Figure 1E).
We then asked whether ginkgolic acid and anacardic acid also
inhibit in vivo protein SUMOylayion by analyzing the effect of
the level of protein SUMOylation in 293T cells expressing Flag-
tagged SUMO (Figure 2A). Immunoblotting with an anti-Flag
antibody showed that ginkgolic acid and anacardic acid reduced
the amount of high-molecular weight SUMO conjugates in a
dose-dependent manner. Treatment with hydrogen peroxide
also reduced the level of high-molecular weight SUMO conju-
gates (Figure 2A; see Figure S1 available online), as recently
reported (Bossis and Melchior, 2006). Time course experiments
revealed that inhibition of in vivo SUMOylation by ginkgolic acid
or anacardic acid can be detected as early as 1 hr after the chal-
lenge (Figure S1). We next examined whether ginkgolic acid canChemistry & Biology 16, 133inhibit the SUMOylation of p53, as p53 can bemodified bySUMO
in vivo on lysine residue 386 (Gostissa et al., 1999; Rodriguez
et al., 1999) (Figure 2B). The level of SUMOylated p53 was mark-
edly reducedby the ginkgolic acid treatment. Importantly, neither
ginkgolic acid nor anacardic acid affected protein ubiquitination
in cells (Figure 2C; Figure S1).
Ginkgolic acid is a structurally simple compound consisting of
salicylic acid and a long-carbon chain substituent. We next
examined which part is important for its inhibitory activity. Sali-
cylic acid (Figure 3A) alone did not affect the in vitro SUMOyla-
tion of RanGAP1-C2 (Figure 3B) or the in vivo SUMOylation of
p53 (Figure 2B), suggesting that the long carbon chain is neces-
sary for its activity. However, because of the comparable or
even stronger activity of anacardic acid, we speculated that
the double bond within the alkyl chain may not be important.
The role of two functional groups in ginkgolic acid, carboxylic
acid and a hydroxyl group, were also examined by testing the
activity of a ginkgolic acid methyl ester (Me-GA, Figure 3A)
and an acetylated derivative of the phenolic hydroxyl group on
ginkgolic acid (Ac-GA, Figure 3A; Figure 3C). Me-GA could not
inhibit the SUMOylation of RanGAP1-C2 even at 10 mM,
whereas Ac-GA retained the ability to inhibit the SUMOylation
of RanGAP1-C2. These results suggest that the carboxylic
acid in ginkgolic acid is indispensable for the inhibitory activity
of ginkgolic acid.
To elucidate the mechanism by which ginkgolic acid inhibits
protein SUMOylation, we synthesized a derivative with the fluo-
rescent substance BODIPY (GA-BODIPY, Figure 4A) as a probe
to investigate the target of ginkgolic acid. Before the detailed
analysis, we confirmed that GA-BODIPY, but not BODIPY alone
(C5-BODIPY, Figure 4A), effectively inhibited the in vitro
SUMOylation of RanGAP1-C2 (Figure S2). When GA-BODIPY
was added to the complete reactionmixture of in vitro SUMOyla-
tion, we observed dose-dependent binding of E1 toGA-BODIPY,
but not C5-BODIPY, in gel electrophoresis in both nondenatured
conditions (Figure 4B) and denatured conditions (Figure S3),
suggesting that E1 is the target of ginkgolic acid. To confirm
this idea, we incubated GA-BODIPY with each recombinant
protein: E1, E2, or GST alone. GA-BODIPY binds only to E1,
but not to E2 or GST (Figure 4C). This binding to E1 is specific,
because ginkgolic acid inhibited the binding between E1 and
GA-BODIPY in a dose-dependent manner (Figure 4D). Impor-
tantly, however, inactive derivatives, salicylic acid and Me-GA,
failed to inhibit the binding. In contrast, the active derivative
Ac-GA could compete for binding (Figure 4D). These results
suggest that E1 is the specific and direct target of ginkgolic
acid, and that the long carbon chain and the carboxylic acid
group of ginkgolic acid are essential for the interaction with E1.Figure 1. Ginkgolic Acid, a Major Component of Ginkgo biloba Extract, Inhibited SUMOylation In Vitro
(A) Indicated concentrations of the extract of Ginkgo biloba leaves (1–100 mg/ml) were added to the SUMOylation reaction mixture containing His-tagged
SUMO-1, His- and T7-tagged RanGAP1-C2, the GST-Aos1-Uba2 fusion protein (E1), and His-tagged Ubc9 (E2) in the presence of 2 mM ATP. SUMOlylated
RanGAP1-C2 was detected by immunoblotting with an anti-T7 or anti-SUMO-1 antibody.
(B) Indicated concentrations of ginkgolic acid or ginkgolides (1–100 mM) were added to the SUMOylation reaction mixture, and then SUMOlylated RanGAP1-C2
was detected as described in (A).
(C) Structure of ginkgolic acid, a major component of Ginkgo biloba extract, and its analog anacardic acid.
(D and E) Inhibition of in vitro SUMOylation by ginkgolic acid and anacardic acid. Ginkgolic acid or anacardic acid at indicated concentrations (1–10 mM) was
added to the reaction mixture, and then SUMOlylated RanGAP1-C2 was detected as described in (A). The level of the SUMOylation of RanGAP1-C2 was deter-
mined bymeasuring the intensity of SUMOylated RanGAP1-C2 by using ImageGauge Version 4.22 (FUJIFILM). The error bars show the standard deviations from
three independent assays, and the IC50 value was calculated by using 50% inhibition compared with a control sample without compounds.–140, February 27, 2009 ª2009 Elsevier Ltd All rights reserved 135
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Ginkgolic Acid as an Inhibitor of SUMOylationFigure 2. Ginkgolic Acid Inhibited SUMOylation In Vivo
(A) Inhibition of in vivo protein SUMOylation by ginkgolic acid and anacardic acid. 293T cells were transfected with Flag-tagged SUMO and then treated with
various concentrations of ginkgolic acid or anacardic acid (10–100 mM) for 4 hr or were treated with 1mMH2O2 for 1 hr. Cells were lysed in RIPA buffer containing
50 mM N-ethylmaleimide, and the lysates were separated by 6% SDS-PAGE, followed by immunoblotting with an anti-FLAG antibody.
(B) Inhibition of in vivo p53 SUMOylation by ginkgolic acid. H1299 cells (p53/) that had been transfected with the indicated combinations of Flag-tagged SUMO,
p53 wild-type, and SUMOylation-deficient mutant K386R were treated with various concentrations of ginkgolic acid, anacardic acid (10–100 mM), or 100 mM
salicylic acid for 18 hr. Cell extracts were immunoprecipitated with an anti-p53 (FL393)-G antibody, followed by immunoblotting with an anti-FLAG or anti-
p53 (Ab-6) antibody. The arrowhead indicates a nonspecific band, and the asterisk indicates antibody heavy chain.
(C) The effects of ginkgolic acid and anacardic acid on in vivo ubiquitination. 293T cells that had been transfected with Myc-tagged ubiquitin were treated with
various concentrations of ginkgolic acid or anacardic acid (10–100 mM) for 4 hr in the presence of 10 mM of the proteasome inhibitor MG132 (in order to increase
the level of ubiquitination by blocking the degradation of ubiquitinated protein). Cells were lysed in RIPA buffer containing 50 mM N-ethylmaleimide, and the
lysates were separated by 6% SDS-PAGE, followed by immunoblotting with an anti-c-Myc antibody.Finally, we sought to determine whether ginkgolic acid and
anacardic acid could block the formation of the E1-SUMO-1
intermediate. The complex of E1 and SUMO-1 biotinylated via
the thioester bond can be detected in the presence of ATP under
nonreducing conditionsbyusing abiotin-avidin detection system
(Uchimuraet al., 2004) (Figure 4E). Thebandcorresponding to the136 Chemistry & Biology 16, 133–140, February 27, 2009 ª2009 ElseE1-biotinylated SUMO-1 intermediate was detected after incu-
bating biotinylated SUMO-1 with E1 in the presence of ATP, but
this band disappeared after the addition of the reducing agent
DTT. The formation of the E1-biotinylated SUMO-1 intermediate
was blocked by ginkgolic acid and anacardic acid in a dose-
dependent manner (Figure 4E). Thus, we conclude that ginkgolicvier Ltd All rights reserved
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Ginkgolic Acid as an Inhibitor of SUMOylationFigure 3. Structure-Activity Relationship of Ginkgolic Acid
(A) Structure of salicylic acid, a ginkgolic acid methyl ester (Me-GA), and an acetylated derivative of the phenolic hydroxyl group on ginkgolic acid (Ac-GA).
(B andC) Effects of salicylic acid, Me-GA, or Ac-GA on in vitro SUMOylation. Various concentrations of the compounds (1–10 mM)were added to the SUMOylation
reaction mixture, and then SUMOlylated RanGAP1-C2 was detected as described in Figure 1A.acid inhibits protein SUMOylation by directly binding to E1 and
thereby blocking the formation of the E1-SUMO-1 intermediate.
Both ginkgolic acid and anacardic acid possess diverse activ-
ities. Ginkgolic acid induces neuronal cell death and activates
protein phosphatase 2C (PP2C) (Ahlemeyer et al., 2001).
However, anacardic acid inhibits the activities of diverse
enzymes, including lipoxygenase (Grazzini et al., 1991) and
HATs (Balasubramanyam et al., 2003), and activates Aurora
kinase A (Kishore et al., 2008). Therefore, it appears that inhibi-
tion of protein SUMOylation is not the only activity of ginkgolic
acid and anacardic acid. Indeed, both ginkgolic acid and anacar-
dic acid inhibited the PCAF-mediated acetylation of histones
in vitro at a concentration of 10 mM, as previously reported (Fig-
ure S4) (Balasubramanyam et al., 2003). The effective concen-
tration was similar to that for inhibition of the SUMOylation of
RanGAP1-C2 in vitro (Figure 1). However, both compounds
could not affect the acetylation of histones in cells even at the
concentration of 100 mM (Figure S4), a concentration that is suffi-
cient to inhibit in vivo protein SUMOylation (Figures 2A and 2B;Chemistry & Biology 16, 133Figure S1). Furthermore, more than 100 mM ginkgolic acid is
necessary for activating PP2C in vitro (Ahlemeyer et al., 2001).
Although anacardic acid inhibited lipoxygenase and activated
Aurora kinase A in vitro at the concentration of 10 mM (Grazzini
et al., 1991; Kishore et al., 2008), it is unclear whether anacardic
acid could affect the in vivo activity of these enzymes. These
observations suggest that SUMOylation is one of most sensitive
enzyme reactions targeted by ginkgolic acid and anacardic acid.
Anacardic acid also exhibits antitumor activity (Rea et al., 2003)
and sensitizes tumor cells to ionizing radiation through inhibition
of nuclear factor-kB (NF-kB) signaling pathways (Sung et al.,
2008), although its molecular mechanism is not yet fully under-
stood. As SUMO conjugation plays an important role in the regu-
lation of NF-kB signaling pathways (Mabb and Miyamoto, 2007),
it seems possible that inhibition of the NF-kB signaling pathways
by anacardic acid is mediated by suppression of the SUMOyla-
tion of proteins regulating NF-kB activity such as IkB or NEMO.
An active derivative, Ac-GA, inhibited not only SUMOylation,
but also the proliferation of cancer cells, whereas the inactive–140, February 27, 2009 ª2009 Elsevier Ltd All rights reserved 137
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Ginkgolic Acid as an Inhibitor of SUMOylationFigure 4. E1 Is the Target of Ginkgolic Acid
(A) Structure of a derivative with fluorescent substance BODIPY (GA-BODIPY) and BODIPY alone (C5-BODIPY).
(B and C) Specific binding of GA-BODIPY to E1. GA-BODIPY, C5-BODIPY, or ginkgolic acid at various concentrations (1–10 mM)was incubated with the SUMOy-
lation reaction mixture containing (B) His-tagged SUMO-1, His- and T7-tagged RanGAP1-C2, GST-Aos1/Uba2, and His-tagged Ubc9 or with either (C)
GST-Aos1/Uba2, His-tagged Ubc9, or GST alone in the presence of ATP. The proteins were separated by SDS-PAGE under nondenaturing conditions (without
2-mercaptoethanol and boiling). The bound protein was detected by using a fluorescence detector with excitation at 488 nm. The amount of each protein was
assessed by SDS-PAGE under the same nondenaturing conditions, followed by immunoblotting with anti-SUMO (SUMO), anti-T7 (RanGAP1-C2), anti-GST (E1),
and anti-Ubc9 (E2) antibodies, respectively. The molecular sizes of each protein detected by immunoblotting were indicated by arrows. The end of nonspecific
background labeling around 25 kDa appeared reproducibly by an unknown reason, although the gel was run to the bottom.138 Chemistry & Biology 16, 133–140, February 27, 2009 ª2009 Elsevier Ltd All rights reserved
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Ginkgolic Acid as an Inhibitor of SUMOylationderivative, Me-GA, did not (Figure S5), suggesting a link between
SUMOylation inhibition and cytotoxicity. However, it is still
unclear whether the various pharmacological activities of these
compounds can be ascribed to inhibition of SUMOylation.
In this study, we show that both the carboxylic group and the
long aliphatic chain are important for inhibition of SUMOylation
by binding to E1. One could speculate that the carboxyl group
of ginkgolic acid, like SUMO, forms a thioester bond with the
sulfhydryl group of the active site cysteine of E1 to inhibit the
formation of the E1-SUMO intermediate. However, this possi-
bility was ruled out, because GA-BODIPY effectively bound to
the inactive E1 C173S mutant, in which the active site cysteine
residue is mutated to serine (Figure S6). The molecular mecha-
nism by which ginkgolic acid binds and inhibits E1 is an impor-
tant issue that should be elucidated in the future. Additional infor-
mation about the structure-activity relationship will be useful for
analyzing the mode of inhibition and also in the design of a novel
SUMOylation inhibitor that lacks the undesirable activities of
ginkgolic acid; such a compound would be more suitable as
a lead compound for drug development.
SIGNIFICANCE
TheposttranslationalmodificationbySUMOhasemergedas
a central regulatory mechanism of protein function, and it
may be implicated in several diseases. In this study, using
an in situ cell-based screening system to select compounds
frombotanical extracts libraries, we identified ginkgolic acid
and anacardic acid as small-molecule inhibitors of protein
SUMOylation. Mechanistically, ginkgolic acid impaired
SUMOylation by blocking the formation of an E1-SUMO thio-
ester complex, by directly binding to E1. Structure-function
analysis demonstrated that both the carboxylic acid group
and the long aliphatic chain are essential for binding to
E1 and for inhibition of SUMOylation. Although a variety of
in vivo activities of ginkgolic acid and anacardic acid
have been reported, it is currently unclear whether their
SUMOylation inhibition is responsible for these activities.
Elucidation of the molecular mechanism by which these
compounds inhibit E1 activity will provide a basis for the
design and development of novel SUMOylation inhibitors.
EXPERIMENTAL PROCEDURES
Experimental Procedures are described in Supplemental Data.
SUPPLEMENTAL DATA
Supplemental Data include Supplemental Experimental Procedures, Supple-
mental References, and six figures and can be found with this article online at
http://www.cell.com/chemistry-biology/supplemental/S1074-5521(09)00034-9.Chemistry & Biology 16, 133ACKNOWLEDGMENTS
We thank Y. Uchimura (Kumamoto University) for a technical suggestion. This
work was supported in part by the Chemical Genomics Research Group
Project, RIKEN Advanced Science Institute, the CREST Research Project,
the Japan Science and Technology Corporation, and a Grant-in-Aid for Scien-
tific Research on Priority Area ‘‘Cancer’’ from the Ministry of Education,
Culture, Sports, Science and Technology of Japan.
Received: November 9, 2008
Revised: January 10, 2009
Accepted: January 14, 2009
Published: February 26, 2009
REFERENCES
Ahlemeyer, B., Selke, D., Schaper, C., Klumpp, S., and Krieglstein, J. (2001).
Ginkgolic acids induce neuronal death and activate protein phosphatase
type-2C. Eur. J. Pharmacol. 430, 1–7.
Alarcon-Vargas, D., and Ronai, Z. (2002). SUMO in cancer–wrestlers wanted.
Cancer Biol. Ther. 1, 237–242.
Balasubramanyam, K., Swaminathan, V., Ranganathan, A., and Kundu, T.K.
(2003). Small molecule modulators of histone acetyltransferase p300. J. Biol.
Chem. 278, 19134–19140.
Bossis, G., and Melchior, F. (2006). Regulation of SUMOylation by reversible
oxidation of SUMO conjugating enzymes. Mol. Cell 21, 349–357.
Dorval, V., and Fraser, P.E. (2007). SUMO on the road to neurodegeneration.
Biochim. Biophys. Acta 1773, 694–706.
Gostissa, M., Hengstermann, A., Fogal, V., Sandy, P., Schwarz, S.E.,
Scheffner, M., and Del Sal, G. (1999). Activation of p53 by conjugation to the
ubiquitin-like protein SUMO-1. EMBO J. 18, 6462–6471.
Grazzini, R., Hesk, D., Heininger, E., Hildenbrandt, G., Reddy, C.C.,
Cox-Foster, D., Medford, J., Craig, R., and Mumma, R.O. (1991). Inhibition
of lipoxygenase and prostaglandin endoperoxide synthase by anacardic
acids. Biochem. Biophys. Res. Commun. 176, 775–780.
Huang, J., and Berger, S.L. (2008). The emerging field of dynamic lysine meth-
ylation of non-histone proteins. Curr. Opin. Genet. Dev. 18, 152–158.
Johnson, E.S. (2004). Protein modification by SUMO. Annu. Rev. Biochem. 73,
355–382.
Kishore, A.H., Vedamurthy, B.M., Mantelingu, K., Agrawal, S., Reddy, B.A.,
Roy, S., Rangappa, K.S., and Kundu, T.K. (2008). Specific small-molecule
activator of Aurora kinase A induces autophosphorylation in a cell-free system.
J. Med. Chem. 51, 792–797.
Mabb, A.M., and Miyamoto, S. (2007). SUMO and NF-kB ties. Cell. Mol. Life
Sci. 64, 1979–1996.
Pickart, C.M. (2001). Mechanisms underlying ubiquitination. Annu. Rev.
Biochem. 70, 503–533.
Rea, A.I., Schmidt, J.M., Setzer,W.N., Sibanda, S., Taylor, C., andGwebu, E.T.
(2003). Cytotoxic activity of Ozoroa insignis from Zimbabwe. Fitoterapia 74,
732–735.
Rodriguez, M.S., Desterro, J.M., Lain, S., Midgley, C.A., Lane, D.P., and Hay,
R.T. (1999). SUMO-1 modification activates the transcriptional response of
p53. EMBO J. 18, 6455–6461.
Rouleau, N., Wang, J., Karras, L., Andrews, E., Bielefeld-Sevigny, M., and
Chen, Y. (2008). Highly sensitive assays for SUMOylation and small ubiqui-
tin-like modifier-dependent protein-protein interactions. Anal. Biochem. 375,
364–366.(D) Competition assay. Ginkgolic acid, salicylic acid, Ac-GA, or Me-GA at indicated concentrations was added with 10 mMGA-BODIPY to GST-Aos1/Uba2 (E1),
and the binding of GA-BODIPY to E1 was detected as described above. The amount of GST-E1 was assessed by immunoblotting with an anti-GST antibody.
(E) Impairment of the thioester bond formation between E1 and biotinylated SUMO-1 by ginkgolic acid or anacardic acid. Ginkgolic acid or anacardic acid at
10 mM (left panel) or various concentrations (0.1–10 mM; right panel) was added to a reaction mixture containing 0.1 mg biotinylated SUMO-1 and 1 mg GST-
Aos1/Uba2 in the presence or absence of 2 mM ATP. After the mixtures had been incubated at 37C for 20 min, they were separated by SDS-PAGE, followed
by analysis with avidin-conjugated horseradish peroxidase. Addition of 1 mM DTT to the reaction completely abolished the complex formation of biotinylated
SUMO-1 and GST-Aos1/Uba2 (left panel).–140, February 27, 2009 ª2009 Elsevier Ltd All rights reserved 139
Chemistry & Biology
Ginkgolic Acid as an Inhibitor of SUMOylationSaitoh, N., Uchimura, Y., Tachibana, T., Sugahara, S., Saitoh, H., and Nakao,
M. (2006). In situ SUMOylation analysis reveals a modulatory role of RanBP2
in the nuclear rim and PML bodies. Exp. Cell Res. 312, 1418–1430.
Sekizawa, R., Ikeno, S., Nakamura, H., Naganawa, H., Matsui, S., Iinuma, H.,
and Takeuchi, T. (2002). Panepophenanthrin, from a mushroom strain, a novel
inhibitor of the ubiquitin-activating enzyme. J. Nat. Prod. 65, 1491–1493.
Sung, B., Pandey, M.K., Ahn, K.S., Yi, T., Chaturvedi, M.M., Liu, M., and
Aggarwal, B.B. (2008). Anacardic acid (6-nonadecyl salicylic acid), an
inhibitor of histone acetyltransferase, suppresses expression of nuclear
factor-kB-regulated gene products involved in cell survival, proliferation,
invasion, and inflammation through inhibition of the inhibitory subunit of
nuclear factor-kBa kinase, leading to potentiation of apoptosis. Blood 111,
4880–4891.140 Chemistry & Biology 16, 133–140, February 27, 2009 ª2009 ElseTsukamoto, S., Hirota, H., Imachi, M., Fujimuro, M., Onuki, H., Ohta, T., and
Yokosawa, H. (2005). Himeic acid A: a new ubiquitin-activating enzyme inhib-
itor isolated from amarine-derived fungus,Aspergillus sp. Bioorg. Med. Chem.
Lett. 15, 191–194.
Uchimura, Y., Nakao, M., and Saitoh, H. (2004). Generation of SUMO-1 modi-
fied proteins in E. coli: towards understanding the biochemistry/structural
biology of the SUMO-1 pathway. FEBS Lett. 564, 85–90.
Yang, X.J., and Seto, E. (2008). Lysine acetylation: codified crosstalk with
other posttranslational modifications. Mol. Cell 31, 449–461.
Yang, Y., Kitagaki, J., Dai, R.M., Tsai, Y.C., Lorick, K.L., Ludwig, R.L., Pierre,
S.A., Jensen, J.P., Davydov, I.V., Oberoi, P., et al. (2007). Inhibitors of ubiqui-
tin-activating enzyme (E1), a new class of potential cancer therapeutics.
Cancer Res. 67, 9472–9481.vier Ltd All rights reserved
